An Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients With Barrett's Esophagus.

Publication

An Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients With Barrett's Esophagus.

Journal Paper/Review - Jun 13, 2023

Duits L C, Khoshiwal Amir M, Frei Nicola Fabian, Pouw Roos E, Smolko Christian, Arora Meenakshi, Siegel Jennifer J, Critchley-Thorne Rebecca J, Thangaiah Judith Jebastin, Barrett's SURF LGD Study Pathologists Consortium

Citation

Duits L, Khoshiwal A, Frei N, Pouw R, Smolko C, Arora M, Siegel J, Critchley-Thorne R, Thangaiah J, Barrett's SURF LGD Study Pathologists Consortium. An Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients With Barrett's Esophagus. Am J Gastroenterol 2023; 118:2025-2032.

Type

Journal Paper/Review (English)

Journal

Am J Gastroenterol 2023; 118

Publication Date

Jun 13, 2023

Issn Electronic

1572-0241

Pages

2025-2032

Brief description/objective

Low-grade dysplasia (LGD) in Barrett's esophagus (BE) is associated with an increased risk of progression to high-grade dysplasia or esophageal adenocarcinoma. However, because of substantial interobserver variability in the diagnosis of LGD, a patient's management plan and health outcome depend largely on which pathologist reviews their case. This study evaluated the ability of a tissue systems pathology test that objectively risk stratifies patients with BE (TissueCypher, TSP-9) to standardize management in a manner consistent with improved health outcomes for patients with BE.